Low-cost knockoffs of the arthritis treatment Remicade in Europe hurt Merck & Co.’s second-quarter sales and earnings, a harbinger of the pressure facing sellers of other costly biotechnology drugs in the coming years.
from WSJ.com: US Business http://ift.tt/1JsF9NN
via IFTTT
No comments:
Post a Comment